Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium.
Sakshi Mehta(Juravinski Cancer Centre), Brandon M. Meyers(North York General Hospital), Winson Y. Cheung(University of Calgary), M-J.D.V.B.A.D.C. Cardoso(Juravinski Cancer Centre), Ravi Ramjeesingh(Queen Elizabeth II Health Sciences Centre), Dawn Elizabeth Armstrong(Dr. H. Bliss Murphy Cancer Centre), Christina Kim, Yoo‐Joung Ko(Sunnybrook Health Science Centre), Shiying Kong(Alberta Health Services), Daniel J. Renouf(BC Cancer Agency), Mohammed Harb(Moncton Hospital), Shahid Ahmed(Emory University)
Cited by 0
Related Papers
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
|Journal of Clinical Oncology|2016|291
Comparisons of Patient and Physician Expectations for Cancer Survivorship Care
|Journal of Clinical Oncology|2009|289
HER2-directed therapy: current treatment options for HER2-positive breast cancer
|Breast Cancer|2015|183